Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

55.75USD
12 Feb 2016
Change (% chg)

$1.67 (+3.09%)
Prev Close
$54.08
Open
$54.16
Day's High
$56.05
Day's Low
$53.88
Volume
1,434,203
Avg. Vol
1,069,862
52-wk High
$72.31
52-wk Low
$53.79

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Company's generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including... (more)

Overall

Beta: 0.87
Market Cap(Mil.): $55,984.29
Shares Outstanding(Mil.): 1,020.62
Dividend: 0.34
Yield (%): 2.45

Financials

  TEVA.N Industry Sector
P/E (TTM): 27.00 30.46 37.46
EPS (TTM): 2.06 -- --
ROI: 5.09 14.83 14.17
ROE: 7.66 15.40 14.92
Search Stocks

Teva says Actavis deal to close by April as profit falls

TEL AVIV Teva Pharmaceutical Industries , the world's largest generics drugmaker, reported a fall in fourth-quarter profit and revenue on lower sales of its top drug and said it expects to close its purchase of Actavis by early April. Israel-based Teva agreed last year to buy Allergan's Actavis generic business for $40.5 billion as well as Mexico's Rimsa for $2.3 billion.

11 Feb 2016

UPDATE 1-Teva says Actavis deal to close by April as profit falls

* Sees Q1 adjusted EPS $1.32-$1.36, revenue $4.7-$4.9 bln (Adds Teva comments, details from conference call)

11 Feb 2016

Teva Pharm Q4 profit, revenue fall as Copaxone sales drop

TEL AVIV, Feb 11 Teva Pharmaceutical Industries , the world's largest generics drugmaker, reported a decline in fourth-quarter profit and revenue as sales of its top drug Copaxone fell in the wake of competition.

11 Feb 2016

EU mergers and takeovers (Feb 8)

BRUSSELS, Feb 8 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

08 Feb 2016

Teva, Active Biotech halt higher doses of oral MS drug in trials

JERUSALEM Teva Pharmaceutical Industries and Active Biotech will discontinue higher doses of their oral drug in development for multiple sclerosis in two trials, citing the occurrence of non-fatal cardiovascular events in eight patients.

04 Jan 2016

Teva, Active Biotech halt higher doses of oral MS drug in trials

JERUSALEM, Jan 4 Teva Pharmaceutical Industries and Active Biotech will discontinue higher doses of their oral drug in development for multiple sclerosis in two trials, citing the occurrence of non-fatal cardiovascular events in eight patients.

04 Jan 2016

U.S. FDA advisers recommend approval of Teva asthma drug for adults

An advisory committee to the U.S. Food and Drug Administration recommended on Wednesday that the agency approve Teva Pharmaceutical Industries Ltd's <TEVA.TA) experimental drug reslizumab for severe asthma in patients aged 18 and older.

10 Dec 2015

Teva gets FDA approval for cancer drug

Israel's Teva Pharmaceutical Industries said the U.S. Food and Drug Administration approved an injectable and infusion version of its cancer drug bendamustine.

08 Dec 2015

Teva divesting $1 billion in assets to clear Allergan deal

Teva Pharmaceutical Industries Ltd is in the process of divesting about $1 billion worth of assets to address antitrust concerns over its deal to buy Allergan Plc's generic drugs business, people familiar with the matter said.

04 Dec 2015

Teva divesting $1 bln in assets to clear Allergan deal -sources

Dec 3 Teva Pharmaceutical Industries Ltd is in the process of divesting about $1 billion worth of assets to address antitrust concerns over its deal to buy Allergan Plc's generic drugs business, people familiar with the matter said.

03 Dec 2015

Competitors

  Price Chg
Novartis AG (NOVN.VX) CHF70.90 +1.35
Biogen Inc (BIIB.OQ) $247.22 +2.11

Earnings vs. Estimates

Search Stocks